Navigation Links
ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Mesenchymal Cells
Date:3/27/2009

ATHENS, Ga., March 27 /PRNewswire/ -- ArunA Biomedical, Inc., announced today that it will make its CELL-EZ(TM) brand hMC(TM) human mesenchymal progenitor cells commercially available to the research community in mid 2009. Derived from pluripotent human embryonic stem cells, ArunA's hMC lines will offer unique, highly proliferative uniform populations of mesenchymal cells in a feeder free monolayer culture.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080819/CLTU003LOGO)

The introduction of our CELL-EZ hMC(TM) cell lines is a significant step forward for stem cell research." Dr. Steven Stice, ArunA CSO and Co-Founder commented, "CELL-EZ hMC(TM) will provide a human cell based format for a wide range of research in areas from osteogenisis to cancer research. Unlike human bone marrow and other tissue derived mesenchymal cells, ArunA's hMC cells have the unique ability to differentiate into osteoblasts and chondrocytes but not adipocytes, making them a unique tool for research and drug discovery directed at areas such as Osteoporosis."

The CELL-EZ hMC(TM) cell lines were further developed by ArunA through a technology license agreement with the University of Georgia using a proprietary platform technology for producing progenitor cells from pluripotent stem cells. The CELL-EZ hMC(TM) cell lines are from a stable genetic background and can be genetically modified to produce constant and more informative research results. This product line compliments ArunA's portfolio of pluripotent stem cell products derived from human embryonic stem cells.

About ArunA Biomedical

Located in Athens, Georgia, ArunA Biomedical, Inc. is a privately held biotechnology corporation dedicated to the discovery, manufacturing and commercialization of emerging new technologies in human embryonic stem cell research for use in drug discovery and basic research. ArunA is the first company to commercialize products derived from human embryonic stem cells and sees its proprietary technology as a catalyst leading to the discovery of novel therapeutic compounds, tests for neurotoxicity and breakthroughs in understanding human development and diseases such as Parkinson's, Alzheimer's, Huntington's and cancer.

For more information, visit: www.ArunAbiomedical.com.

This press release contains forward-looking statements regarding the company's potential impact on scientific research. Certain conditions could alter the outcome or progress of these statements including but not limited to unexpected manufacturing issues, product performance and quality control/assurance issues. Forward- looking statements are based on the opinions, beliefs and expectations of the company or individuals quoted in the press release and the company does not assume any obligation to update these forward-looking statements if circumstances change.


'/>"/>
SOURCE ArunA Biomedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
2. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
3. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
4. ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells
5. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
6. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
7. Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test
8. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
9. NCIIA Announces Launch of 4th Annual Student Biomedical Innovation Competition
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
(Date:6/22/2016)... Research and Markets has announced the addition of the ... The global biomarkers market ... 2013. The market is expected to grow at a five-year compound ... from $50.6 billion in 2015 to $96.6 billion in 2020. ... (2015 to 2020) are discussed. As well, new products approved in ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):